title: [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
abstract: In diabetes, metabolic syndrome, some types of familial dyslipidemia, ischemic pathology of atheromatous origin and renal failure, the presence of mixed dyslipidemia is common. In other words, there is an excess of cholesterol and triglycerides, associated or not with HDL-c deficiency. These clinical conditions are associated with high to very high cardiovascular risk. It is appropriate when treating these conditions to achieve an overall control of lipid metabolism abnormalities, in terms of excess cholesterol carried by atherogenic lipoproteins (LDL-c and non-HDL-c) and triglyceride excess and deficit of HDL-c. To achieve this overall control is necessary to correct the potential causes of secondary dyslipidemia, improve lifestyle habits and use a drug from the statin family, and it is often necessary to combine a drug from the fibrate family. This combination has been shown to be effective and safe in the overall control of dyslipidemia and the cardiovascular risk prevention in patients at high risk. This combination has been shown to have a favorable eff ect in the population with diabetes and microangiopathy, both in the retina and in the glomerulus. For patients with moderate renal failure, the use of fibrates is controversial, and there are marked disagreements between the recommendations issued by various organizations and expert consensus groups.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona, España. CIBERobn, FIPEC, IDIBELL, Universitat de Barcelona, Barcelona, España. Electronic address: xpinto@bellvitgehospital.cat.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D011345:Fenofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D017035:Pravastatin; D011345:Fenofibrate
keywords: Combined therapy with fibrates and statins; Diabetes mellitus; Dislipemia mixta; Insuficiencia renal; Metabolic syndrome; Mixed dyslipidemia; Renal failure; Riesgo vascular; Síndrome metabólico; Terapia combinada con fibratos y estatinas; Vascular risk